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RabbitSerological memory after inoculation of protective antigen (PA) combined with Alhydrogel adjuvant
(PA/Alhydrogel) was examined in New Zealand white rabbits, an animal model for anthrax. A threshold
dose of 0.1 lg of PA/Alhydrogel was identiﬁed which resulted in an ELISA titer 2 weeks after a primary
immunization of only 0.168 lg anti-PA IgG per ml and a toxin-neutralizing antibody titer (TNA ED50)
of 1.8 (n = 40). A signiﬁcant increase in anti-PA IgG and TNA ED50 titers were measured (p < 0.0001)
2 weeks after a booster immunization with 0.1 lg of PA/Alhydrogel at 14 days (n = 10; 40.9 lg anti-PA
IgG per ml; 522 TNA ED50) and 28 days (n = 10; 63.8 lg anti-PA IgG per ml; 501 TNA ED50). At this thresh-
old dose of PA/Alhydrogel, protection against an aerosol exposure to Bacillus anthracis Ames spores
improved as the booster immunization was administered from 4 days (40% survival), to 8 days (50% sur-
vival), and to 12 days (80% survival) before challenge. The partial protection of rabbits, even in the
absence of protective antibody titers (0.9 lg anti-PA IgG per ml and 26 TNA ED50) when the booster
immunization was administered 4 days before challenge, suggested a protective potential for serologic
memory.
Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommon-
s.org/licenses/by/4.0/).1. Introduction
Human infection with Bacillus anthracis, which generally is
caused by contact with infected animals or spore-contaminated
animal products, may be manifested as cutaneous, inhalational,
or gastrointestinal anthrax, suggesting the route of exposure. The
establishment of anthrax is generally based upon the presence of
two major virulence factors, a poly-c-D-glutamic acid capsule and
a tripartite exotoxin. The capsule enhances virulence by inhibiting
phagocytosis of the bacterium, resulting in a massive bacteremia
[1]. The tripartite exotoxin is formed by competitive binding of
either lethal factor (LF) or edema factor (EF) with protective anti-
gen (PA) to form lethal toxin (LeTx) or edema toxin (EdTx), respec-
tively. PA, an essential component in the formation of each toxin,binds to cell surface receptors, oligomerizes after undergoing pro-
teolytic activation, then binds and translocates LF and EF into the
cytosol [2,3]. LF is a metalloprotease that targets most isoforms
of mitogen-activated protein kinase kinase [4,5] and EF is a
calmodulin-dependent adenylate cyclase [6]. Early establishment
of infection is effected by both LeTx and EdTx by impairing the
immune system [3,7]. As the infection progresses, LeTx targets car-
diomyocytes and vascular smooth muscle cells while EdTx causes
edema within the intestinal lumen and liver [7–9].
People at risk of infection in the United States are immunized
with a chemical-based vaccine, anthrax vaccine adsorbed (AVA
BioThrax) while anthrax vaccine precipitated (AVP) serves as the
clinical vaccine in the United Kingdom. The major protective
immunogen in these vaccines is PA [10,11]. Recombinant PA vacci-
nes are currently in clinical trials [12–14]. Antibody responses
measured by an anti-PA IgG enzyme linked immunosorbent assay
(ELISA) and an in vitro LeTx neutralizing antibody (TNA) assay, in
which the functional activity of antisera are evaluated in a macro-
phage cytolysis assay, have been identiﬁed as serological correlates
of immunity in non-human primates, rabbits, and guinea pigs [15–
20].
The current study was conducted to further develop the rabbit
animal model for anthrax by examining serological memory by
identifying a threshold dose of PA which does not produce an
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booster injection. The protective capacity of serologic memory at
the threshold dose was examined relative to the timing of a boos-
ter injection against an aerosol spore challenge. Also, the primary
and secondary antibody response proﬁles in rabbits injected with
a protective dose of PA were examined.2. Materials and methods
2.1. New Zealand white rabbits
An equal number of male and female New Zealand white (NZW)
rabbits (3.0–3.5 kg) (Harlan Bioproducts for Science, Indianapolis,
IN and Covance Research Products, Denver, PA) were used in the
studies.
2.2. Immunization screening
The threshold dose of PA for rabbits was chosen by injecting
rabbits intramuscularly (i.m.) on days 0 and 14 with either 10 lg,
1 lg, 0.1 lg, 0.01 lg, or 0 lg of PA (List Biological Laboratories,
Campbell, Calif.) diluted in PBS in a volume of 0.5 ml, each
adsorbed to 1 mg of aluminum per ml (Alhydrogel, 2% Al2O3; HCl
Biosector, Frederikssund, Denmark; PA/Alhydrogel) for >2 days at
4 C before use. Control rabbits were injected with PBS adsorbed
to Alhydrogel (PBS/Alhydrogel). Two weeks after the primary injec-
tion and booster injection (days 14 and 28), blood was collected
and serum was tested for the presence of antibodies to PA ELISA
and TNA titers. After determining the threshold dose of PA for rab-
bits (0.1 lg PA/Alhydrogel, see Section 3), additional booster injec-
tions of the threshold dose of PA used in the primary injection were
given at either 28 days, 84 days, or 168 days after the primary
injection to examine the effect on the memory antibody response.
Blood was collected 2 weeks after the booster injection (day 42,
day 98, and day 182, respectively) and serum was tested for the
presence of antibodies to PA ELISA and TNA titers.
The primary and secondary antibody response proﬁles were
examined by injecting rabbits i.m. with 50 lg of PA/Alhydrogel
on days 0 and 21 and collecting blood periodically to test serum
for the presence of antibodies to PA and TNA titers in the serum.
2.3. Protection against aerosol exposure
Rabbits were injected i.m. with 0.1 lg of PA/Alhydrogel and
boosted with 0.1 lg of PA/Alhydrogel 4 days (day 86), 8 days
(day 82), or 12 days (day 78) before aerosol exposure on day 90 fol-
lowing the primary immunization. The initial immunizations were
staggered to permit challenge of 10 rabbits from each group on the
same day for all the groups. The remaining 4 rabbits from each
group were used for serology testing after the challenge date.
Challenge controls (n = 8), which received PBS/Alhydrogel, were
likewise divided; 6 were challenged and 2 were used for serology
testing. Aerosol exposure (head only) was performed with a lethal
dose of spores from the Ames isolate of B. anthracis as previously
described [15]. Survival was noted for 21 days after challenge.
Moribund animals were humanely euthanized. The aerosol LD50
of Ames spores in NZW rabbits is 1.1  105 spores [15]. The inhaled
dose of spores (average LD50 ± SD) for the two hood lines were
139.6 ± 64.23 spores and 82.2 ± 44.24 spores (total average
110.9 ± 61.64 spores).
2.4. Serological analysis of antibodies
A quantitative anti-PA IgG ELISA was performed as described
[17]. Brieﬂy, PA-coated plates were sequentially incubated withdilutions of each sample in triplicate, HRP-conjugated goat
anti-rabbit IgG(H + L), then ABTS substrate. Samples were diluted
in PBS, 0.1% Tween 20, 5% non-fat dry milk (PBSTM) and plates
were washed between steps using PBS, 0.1% Tween 20 (PBST).
Titers were calculated from the average absorbance value for trip-
licate wells of each sample with the absorbance values of the afﬁn-
ity puriﬁed rabbit anti-PA IgG standard curve by linear regression
analysis and reported as micrograms of anti-PA IgG per ml (KC4
software, BioTek Instruments, Winooski, Vt.) as described [17]
and recorded as the geometric mean (GM) and standard error of
the geometric mean (SEM) from triplicate dilutions [21]. The low-
est sample starting dilution ratio was 1:50. Negative samples that
were not extrapolated from the standard curve were set at
0.036 lg of IgG per ml.
For the TNA assay, J774A.1 cells were exposed to ﬁnal concen-
trations of 100 ng of PA per ml and 50 ng of LF per ml (List
Biological Laboratories) in the presence of antibody as described
[17]. After incubating for 4 h, MTT was added for 2 h before lysing
the cells and solubilizing the reduced formazin. The percent viabil-
ity, determined using the following formula, % viability = (((test
avg  LeTx avg)/(media avg  LeTx avg))  100), was plotted
against each respective test dilution using a 4-parameter logistic
equation algorithm and TNA assay titers were expressed as the
reciprocal of the dilution of antiserum that neutralized the cyto-
toxic activity of LeTx on J774A.1 cells at 50% of control values
(ED50) using XLﬁt software (IDBS, Inc., Emeryville, Calif.) as
described [17]. TNA titers were recorded as the GM ED50 (SEM)
[21]. The starting dilution for the TNA assay was 1:50 and negative
samples that could not be quantiﬁed from the standard curve were
assigned an ED50 value of ‘1’.2.5. Avidity measurement
Antibody avidity was measured by modifying the ELISA [17].
After incubating twofold sample titrations on the ELISA plates for
2 h, the plates were washed and triplicate sample titrations were
incubated for 15 min with either 1.5 M sodium thiocyanate or
PBSTM. The plates were washed and the ELISA procedure resumed
by adding the secondary antibody. The avidity was evaluated by
comparing the respective absorbance values (A405nm) of the
1:800 dilutions of sera samples incubated in either 1.5 M sodium
thiocyanate or PBSTM.2.6. Data analysis
ELISA titers, TNA ED50 titers, and avidity absorbance values
were log10 transformed. ELISA and TNA ED50 titers were compared
using either unpaired t test with Welch’s correction (to examine
samples between groups) or paired t-test (to examine samples
within a group), as appropriate. Comparisons between avidity
absorbance values within each group were performed using
repeated measure one-way ANOVA with the Greenhouse-Geisser
correction and Bonferroni’s multiple comparison test or paired t
test, as appropriate. Comparisons between absorbance values
between groups were performed using one-way ANOVA with
Tukey’s multiple comparison test. The antibody response over time
was analyzed against the preceding primary or booster immuniza-
tion by one-way ANOVA with repeated measures using
Holm-Sidak’s multiple comparison test. Survival curves, which
plotted the percent survival as a function of time, were compared
by log-rank (Mantel-Cox) test and MTTD were compared by
unpaired t test with Welch correction. Statistical analysis was per-
formed by using GraphPad Prism 6 (GraphPad Software, La Jolla,
Calif.) and p-values were two-sided.
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3.1. Selection of PA/Alhydrogel threshold dose for rabbits
To examine serological memory in the rabbit, we ﬁrst deter-
mined the concentration of PA that would not produce an
anti-PA antibody response by ELISA after the primary injection
but would result in a measurable memory antibody response in
the majority of animals after a booster injection. Each test group
was injected i.m. on days 0 and 14 with 10 lg, 1 lg, 0.1 lg,
0.01 lg, or 0 lg of PA/Alhydrogel. Blood was collected 2 weeks
after each injection (days 14 and 28) for serum antibody analysis.
A dose dependent serological response was measured for each
PA/Alhydrogel dosage group (Table 1). Two weeks after the pri-
mary injection with either 10 lg or 1 lg of PA, GM antibody titers
of >3 lg of anti-PA IgG per ml and >50 TNA assay ED50 were mea-
sured in the majority of rabbits. However, at a suboptimal concen-
tration of 0.1 lg PA, only 1 of 10 rabbits had a PA ELISA titer >3 lg
of anti-PA IgG per ml (at 4.97 lg anti-PA IgG per ml) and none of
the animals had neutralizing antibody ED50 titers >50 (Table 1).
A 0.01 lg dose of PA did not elicit a primary anti-PA ELISA antibody
titer or a TNA ED50 titer. Two weeks after the day 14 booster injec-
tion, all the rabbits in the groups injected with either 10 lg, 1 lg,
or 0.1 lg of PA had signiﬁcantly higher ELISA and TNA ED50 titers
compared to 2 weeks after the primary immunization that were
dose dependent while the 0.01 lg dose of PA did not result in a
measurable memory antibody response in the rabbits (Table 1).
An initial injection of 0.1 lg of PA did not produce an appreciable
antibody response but this threshold dose did sensitize B-cells to
cause a memory antibody response after a booster injection of
the same PA concentration as the primary injection (Table 1). In
contrast, this threshold concentration of PA was 10-fold less than
what was reported for guinea pigs [22]. While 1 lg of PA did not
produce a measurable ELISA or LeTx neutralization titer after the
ﬁrst injection in guinea pigs, 2 weeks after the booster injection
at day 14, 8 of 10 guinea pigs had measurable ELISA titers and 7
of 10 guinea pigs had measurable LeTx neutralizing titers [22].
The timing of the booster injection that would result in a robust
memory antibody response for the threshold dose (0.1 lg of
PA/Alhydrogel) for rabbits was examined by administering aTable 1
Antibody response after primary and booster immunizations with various doses of
PA.
PA (lg)a Antibody response 2 weeks
after primary immunization
Antibody response 2 weeks
after booster immunization
Anti-PAb TNAc Anti-PA TNA
10 11.9 (1.425) 237.4 (1.332) 306.1 (1.138)d 4821 (1.142)d
(9/10) (10/10) (10/10) (10/10)
1 5.1 (1.426) 60.9 (2.127) 156.8 (1.148)d 2133 (1.204)e
(7/10) (8/10) (10/10) (10/10)
0.1 0.17 (1.747) 1.4 (1.414) 40.9 (1.252)d 522 (1.208)d
(1/10) (0/10) (10/10) (10/10)
0.01 0.04 (1.139) 1 (1.000) 0.1 (1.472) 5 (1.675)
(0/10) (0/10) (0/10) (0/10)
0 0.04 (1.210) 1 (1.000) 0.06 (1.659) 2 (2.031)
(0/4) (0/4) (0/4) (0/4)
a Rabbits in each group (n = 10) were injected with the same of one of four doses
of PA/Alhydrogel on days 0 and 14. Controls (n = 4) received PBS/Alhydrogel.
b GM anti-PA ELISA titer (lg anti-PA IgG per ml) and (SEM). The number of
positive responders (titers >3 lg anti-rPA IgG per ml) over total are shown beneath
in parentheses.
c The GM TNA ED50 titer (SEM) and number of positive responders (titers >50)
over total are shown beneath in parentheses.
d The two-tailed p-value was p < 0.0001 comparing the respective titers 2 weeks
after the primary injection and 2 weeks after the booster injection.
e The two-tailed p-value was p = 0.0004 comparing the respective titer 2 weeks
after the primary immunization and 2 weeks after the booster injection.booster dose 14 days (described above), 28 days, 84 days, and
168 days after the primary injection of 0.1 lg of PA/Alhydrogel
(Table 2). Two weeks after the primary immunization with 0.1 lg
of PA/Alhydrogel, only 7.5% (3 of 40 rabbits, all four groups
included) had ELISA titers >3 lg of anti-PA and 5% (2 of 40 rabbits,
all four groups included) had TNA titers >50 (Table 2). Two weeks
after the booster injections, signiﬁcant increases in the anti-PA
ELISA and TNA ED50 antibody responses were measured compared
to titers measured 2 weeks after the primary injection in all groups
except in the ELISA titers in the booster day 168 group (Table 2).
The ELISA and TNA ED50 titers were lower when the booster injec-
tions were given on days 84 and 168 (Table 2). Two weeks after the
booster injections the anti-PA ELISA titers were not signiﬁcantly
different between the day 14 and day 28 booster groups
(p = 0.3372) but both the day 14 and 28 booster groups were sig-
niﬁcantly different with the day 84 booster group (p = 0.0238 and
p = 0.0087, respectively) and the day168 booster group
(p = 0.0272 and p = 0.0120, respectively). Two weeks after the
booster injections the TNA ED50 titers were not signiﬁcantly differ-
ent between the day 14 and the day 28 and day 84 booster groups
(p = 0.9060 and p = 0.0648, respectively) and between the day 28
and day 84 booster groups (p = 0.0778) while both the day 14
and 28 booster groups were signiﬁcantly different with the day
168 booster group (p = 0.0081 and p = 0.0102, respectively). Thus,
at a threshold dosage of 0.1 lg of PA/Alhydrogel, it appeared that
for a suitable memory antibody response for rabbits, the booster
injection should be given around 2–4 weeks after the primary
immunization. In contrast, guinea pigs injected with 1 lg of PA
had endpoint anti-PA and TNA antibody titers of 381 and 331,
respectively, 2 weeks after the booster injection given at 14 days
after the primary injection, and anti-PA endpoint ELISA antibody
titers of between 7000 and 12,000 and TNA endpoint titers
between 8000 and 12,000 2 weeks after a booster immunization
given at either days 28, 65, or 180 after the primary injection [22].3.2. Avidity ELISA
The maturation of an antibody response after immunization or
infection can be characterized by the antibody avidity or afﬁnityTable 2
Serological response of rabbits injected with 0.1 lg of PA/Alhydrogel and boosted at
different time intervals.a
Booster day group Antibody titer
2 weeks after primary 2 weeks after booster
ELISAb TNAc ELISA TNA
Day 14d 0.17 (1.747) 1.4 (1.414) 40.9 (1.252)e 522 (1.208)e
(1/10) (0/10) (10/10) (10/10)
Day 28 0.24 (1.776) 2.5 (1.826) 63.8 (1.432)e 501 (1.334)e
(1/10) (2/10) (10/10) (10/10)
Day 84 0.17 (1.575) 2.3 (1.521) 11.8 (1.542)e 113 (2.042)f
(0/10) (0/10) (8/10) (8/10)
Day 168 0.12 (1.680) 1.5 (1.453) 5.7 (2.086)g 65 (1.847)e
(1/10) (0/10) (8/10) (6/10)
a Rabbits in each group were injected with 0.1 lg of PA/Alhydrogel on day 0 and
boosted on different days.
b GM ELISA titer (lg of anti-PA IgG per mil) and (SEM). The number of responders
that had titers >3 lg anti-PA IgG per ml over total are shown beneath in
parentheses.
c The GM TNA ED50 titer (SEM) and number of positive responders (titers >50)
over total are shown beneath in parentheses.
d Data reproduced from Table 1.
e The two-tailed p-value was p < 0.0001 comparing the respective titers 2 weeks
after the primary injection and 2 weeks after the booster injection.
f The two-tailed p-value was p = 0.0003 comparing the respective titer 2 weeks
after the primary immunization and 2 weeks after the booster injection.
g The two-tailed p-value was p = 0.8275 comparing the respective titer 2 weeks
after the primary immunization and 2 weeks after the booster injection.
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binding by a chaotropic ion. The presence of high-avidity antibody
is characteristic of a memory response. Avidity determinations
were reported as the absorbance values (A405nm) at 1:800 dilutions
of sera in the presence of 1.5 M sodium thiocyanate. The absor-
bance values of sera obtained 14 days after the primary series were
signiﬁcantly lower after incubation in 1.5 M sodium thiocyanate
compared to incubation in PBSTM for 1 lg PA/Alhydrogel
(p = 0.0060) and 0.1 lg PA/Alhydrogel (p < 0.0001) (Fig. 1). For con-
venience, day 14 control and test samples from the four 0.1 lg
PA/Alhydrogel groups were combined in Fig. 1. Two weeks after
a booster injection the avidity increased signiﬁcantly with 10 lg
PA/Alhydrogel (p = 0.0453) and 1 lg PA/Alhydrogel (p = 0.0027)
compared to the respective day 14 avidity values (Fig. 1). For rab-
bits injected and boosted at different times with 0.1 lg of
PA/Alhydrogel, the increase in avidity for samples incubated in
1.5 M sodium thiocyanate 2 weeks after the booster dose com-
pared to 2 weeks after the respective primary dose were signiﬁ-
cant; days 14 and 28 (p < 0.0001), days 14 and 42 (p = 0.0002),
days 14 and 98 (p < 0.0001), and days 14 and 182 (p < 0.0001).
Two weeks after a booster injection the avidity was signiﬁcantly
higher for the 10 lg and 1 lg doses of PA/Alhydrogel compared
with the 0.1 lg PA/Alhydrogel day 28 booster group (p = 0.0014
and p = 0.0021, respectively) and day 182 booster group
(p = 0.0019 and p = 0.0028, respectively). The avidities of the four
0.1 lg PA/Alhydrogel groups 2 weeks after the booster injection
were not signiﬁcantly different; day 28 and day 42 (p = 0.6552),
day 98 (p = 0.6577) and day 182 (p > 0.9999), day 42 and day 98
(p > 0.9999) and day 182 (p = 0.7110) and day 98 and day 182
(p = 0.7134).
3.3. Antibody response proﬁle to PA in rabbits
Protecting rabbits against an anthrax spore challenge in general
depends on how rapidly the infection develops, the level of protec-
tive antibodies at the time of challenge, and how quickly the mem-
ory antibody response is, among other factors. The memory
antibody response, which is characterized by a more rapid rise
and a higher antibody titer compared to the primary immunization
antibody response, was examined by injecting rabbits i.m. on days
0 and 21 with 50 lg of PA/Alhydrogel. This dose of PA/AlhydrogelPA dose, serum sample day, and test group
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Fig. 1. Avidity expressed as ELISA absorbance values (A405nm) at 1:800 dilutions of
sera from rabbits 2 weeks after a primary and booster injection with PA/Alhydrogel
comparing a 15 min incubation in PBSTM buffer (h, C) or 1.5 M sodium thiocynate
(j, T). Rabbits in each group (n = 10) were injected i.m. on day 0 and boosted with
the same of one of three doses of PA/Alhydrogel (10 lg, 1 lg, or 0.1 lg) on days 14,
28, 84, or 168. Sera were collected 14 days after the primary (day 14) and booster
(day 28, day 42, day 98, and day 182, respectively) injections. Day 14 control and
test samples from the four 0.1 lg PA/Alhydrogel groups were combined.was selected so that an antibody response would be measured
after the primary as well as the booster injections. After the pri-
mary immunization, quantitative anti-PA IgG ELISA and TNA ED50
titers increased signiﬁcantly on day 8 (p = 0.0078 and p = 0.0283,
respectively) and peaked at 12–14 days (Fig. 2). The antibody titers
decreased slightly thereafter and remained relatively stable until
the booster immunization on day 21. After the booster injection,
quantitative anti-PA IgG ELISA and TNA ED50 titers increased sig-
niﬁcantly 4 days later (p = 0.0003 and p < 0.0001, respectively)
and peaked 6–8 days later (Fig. 2). Marcus et al. [22] reported that
anti-PA titers and neutralizing antibody titers were detected in
guinea pigs that had been injected subcutaneously (s.c.) with
25 lg of PA by day 10 and day 12, respectively with peak titers
by day 14. After the booster injection, anti-PA titers were detected
on day 6 and neutralizing antibody titers were detected on day 8
with peak titers 14 days after the booster injection. Results sug-
gested that rabbits responded slightly earlier than guinea pigs after
a booster immunization in that increased ELISA and TNA titers
were measured on days 4–6 for rabbits compared to days 6–8 for
guinea pigs.3.4. Association between memory antibody response and protective
immunity
The timing of the booster injection relative to the protection
afforded rabbits was examined against an aerosol B. anthracis
Ames spore challenge. Rabbits were injected with 0.1 lg of
PA/Alhydrogel on day 0 and boosted 4 days (day 86), 8 days
(day 82), or 12 days (day 78) before an aerosol exposure to B.
anthracis Ames spores on day 90. When rabbits were boosted
4 days, 8 days, or 12 days before challenge, survival increased
signiﬁcantly from 4 of 10 rabbits (40%; p = 0.0220), 5 of 10 rabbits
(50%; p < 0.0001), and 8 of 10 rabbits (80%; p = 0.0002), respec-
tively compared to the challenge controls (0 of 6 rabbits)
(Table 3). Protection improved when time for the memory anti-
body response was increased. On the day of challenge, the 4 days,
8 days, and 12 days serology groups had anti-PA IgG ELISA
titers of 0.9, 39.5, and 32.0 lg IgG per ml and TNA ED50 titers of
26, 581, and 439, respectively (Table 3). One week after the booster
injection, the ELISA and TNA titers were relatively similar across
the groups; ELISA titers were 32.2, 35.2, and 28.0 lg of anti-PA
IgG and TNA ED50 titers were 413, 506, and 464 for the 4 days,
8 days, or 12 days booster groups, respectively (Table 3).
Although the 8 day and 12 day groups had similar ELISA and
TNA titers at the time of their challenge, slightly fewer rabbits sur-
vived in the day 8 group compared to the 12 day group which
was not signiﬁcantly different (p = 0.1904) while the MTTD were
similar, 8.0 and 7.5 days, respectively. For guinea pigs, a booster
injection given 2 or 4 days before challenge resulted in 29% and0 4 8 12 16 20 24 28 32 36 40
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Fig. 2. Serum antibody response after primary and booster injections of 50 lg of
PA/Alhydrogel on days 0 and 21. Anti-PA IgG ELISA titer (s) and TNA ED50 titer (h).
Table 3
Survival against aerosol exposure to B. anthracis Ames spores and antibody response of rabbits boosted on different days.a
Booster day Test group Antibody response 2 weeks
after primary
immunization
Antibody response on day
of booster
Antibody response on day of
challenge
Efﬁcacy against
challenge
Anti-PAb TNAc Anti-PA TNA Anti-PA TNA S/Td Mean TTD
4 days 1-Challenge 0.5 (1.72) 3 (1.80) 0.3 (1.49) 1 (1.00) n/ae n/a 4/10 3.2
(1/10) (1/10) (0/10) (0/10)
1-Serology 0.5 (2.44) 7 (2.96) 0.7 (3.25) 11 (4.25) 0.9 (2.71) 26 (3.33) n/a n/a
(0/4) (0/4) (1/4) (0/4) (1/4) (1/4)
8 days 2-Challenge 0.2 (1.77) 2 (1.78) 0.2 (1.41) 1 (1.00) n/a n/a 5/10 8.0
(1/10) (1/10) (0/10) (0/10)
2-Serology 1.0 (2.12) 17 (2.58) 0.9 (1.83) 2 (2.26) 39.5 (1.21) 581 (1.13) n/a n/a
(1/4) (1/4) (0/4) (0/4) (4/4) (4/4)
12 days 3-Challenge 0.4 (1.59) 2 (1.73) 0.5 (1.55) 1 (1.00) n/a n/a 8/10 7.5
(1/10) (2/10) (1/10) (0/10)
3-Serology 0.08 (1.33) 1 (1.00) 0.1 (1.35) 1 (1.00) 32.0 (1.31) 439 (1.23) n/a n/a
(0/4) (0/4) (0/4) (0/4) (4/4) (4/4)
Controls 4-Chall. 0.04 (1.14) 1 (1.00) 0.06 (1.50) 1 (1.00) n/a n/a 0/6 2.5
(0/6) (0/6) (0/6) (0/6)
4-Serol. 0.04 (1.00) 1 (1.00) 0.05 (1.36) 1 (1.00) 0.04 (1.00) 1 (1.00) n/a n/a
(0/2) (0/2) (0/2) (0/2) (0/2) (0/2)
a Rabbits received primary and booster immunizations of 0.1 lg of PA/Alhydrogel, the latter which were given at 4 days (day 86), 8 days (day 82), or 12 days (day 78)
before aerosol challenge. Each challenge group consisted of 10 animals and each serology group contained 4 animals. Controls contained six animals for challenge controls
and 2 animals for serology analysis.
b GM anti-PA ELISA titers (lg anti-PA IgG per ml) and (SEM). The number of positive responders with titers >3 over the number of animals in the test group are shown
beneath in parentheses.
c GM TNA ED50 (SEM) and number of positive responders with titers >50 over the number of animals in the test group are shown beneath in parentheses.
d S/T, survivors over total.
e n/a, not applicable.
54 S.F. Little, W.M. Webster / Trials in Vaccinology 4 (2015) 50–5533% protection, respectively against an intradermal challenge with
B. anthracis Vollum spores whereas a booster given 6, 8 or 12 days
before challenge was protective at 65%, 90% and 100%, respectively
[22]. For both rabbits and guinea pigs, a protective memory
response was elicited with two injections of a threshold vaccine
dose which appeared to be lower in the rabbit (0.1 lg of PA) than
the guinea pig (1.0 lg of PA). Guinea pigs, however, had elevated
antibody responses after the booster for a longer period of time,
up to 180 days [22], compared to rabbits. In both the guinea pig
and rabbit animal models, the memory response reported for gui-
nea pigs to PA/Alhydrogel which occurred on days 6–8 [22] and the
development of a memory response for rabbits which occurred on
days 4–6 after a booster injection of PA/Alhydrogel was later than
the time-to-death of control animals from anthrax at 2–3 days for
guinea pigs [22] and rabbits challenged with B. anthracis Vollum or
Ames spores, respectively. Marcus et al. [22] observed partial pro-
tection of guinea pigs boosted with 1 lg PA 2–4 days before chal-
lenge in the absence of neutralizing antibody titers. When the
booster was administered at 6, 8, or 12 days before challenge, sur-
vival increased appearing to correlate with neutralizing and
anti-PA titers [22]. Similarly, rabbits were partially protected after
receiving a suboptimal booster injection with 0.1 lg PA/Alhydrogel
4 days before aerosol challenge in the absence of meaningful
anti-PA and TNA ED50 titers at the time of challenge suggesting a
role for serological memory in rabbits. Additionally, when the sub-
optimal booster injection was administered to rabbits 8 days
before aerosol challenge, there was a signiﬁcant increase in sur-
vival (p = 0.0002) and a signiﬁcant increase in MTTD (p = 0.0350)
compared to the control animals, again supporting a role for sero-
logical memory in the rabbit.
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